Please assess the completion status of the following clinical trial:

Trial Title: Gabapentin Versus Transdermal Fentanyl Matrix for Chronic Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients are 20 years of age or older~* patients had chronic pain for more than 3 months and average pain score for last 3 days is not less than 4 (NRS)~* neuropathic pain caused by the spinal stenosis (radiating pain, motor or sensory change~* positive MRI finding or radiculopathy was confirmed by the EMG/NCS or not less than 12 points in the S-LANSS score assessment~* patients who can make out the questionnaire~* patients have agreed with the informed consent~Exclusion Criteria:~* patients who have experience with gabapentin, pregabalin, fentanyl matrix, long-acting strong opioid (CR oxycodone, SR morphine)~* patients who have other causes of neuropathy such as hypothyroidism, Vit B12 deficiency, connective tissue disease, etc.~* patients who have other disease which causes more pain compared with neuropathic pain~* patients with a history of drug or alcohol abuse~* patients who are pregnant or have the possibility of pregnancy~* patients who are unable to use a transdermal system due to skin disease~* patients with a serious mental disease~* patients with a history of hypersensitivity to opioid analgesics~* patients with a chronic pulmonary disease or respiratory depression~* patients combined with industrial accidents or traffic accidents~* at investigator's discretion, any condition where a subject cannot take part in the clinical study on the ground of warning, cautions, and prohibition in study investigator's brochure

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Transdermal fentany matrix (Type: EXPERIMENTAL): Transdermal fentanyl matrix is second-line medication on the neuropathic pain but gabapentin is the first-line medication. So, transdermal fentanyl matrix is experimental arm and gabapentin is active comparator arm.
- gabapentin (Type: ACTIVE_COMPARATOR): Gabapentin is the first-line medication in neuropathic pain. So, gabapentin is active comparator in this study and transdermal fentanyl matrix is experimental.

Based on this trial design, predict the completion outcome and termination type (if applicable).